Back to News
Market Impact: 0.35
Teva, Sanofi Report Sustained Duvakitug Benefits In Phase 2b IBD Study
Source: Nasdaq
Healthcare & Biotech
Teva and Sanofi reported positive long-term Phase 2b data for investigational duvakitug, with sustained improvements in ulcerative colitis and Crohn’s disease through Week 44 of the RELIEVE UCCD extension. The provided article text contains no numerical efficacy results or further details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
SNY0.60
TEVA0.60
More News
- A top medical technology stock is trading at a big discount. Here's why I'm buying
- Obsessed with CoreWeave and the AI trade? You're missing out on some great stocks
- Why is Intuitive Surgical stock sliding today?
- UnitedHealthcare and Humana are ending Medicare Advantage plans for nearly 1 million people
- Alpha Teknova stock tumbles on public offering announcement
- Disc Medicine prices $450 million stock offering at $75/share